Restore maintained at outperform by RBC

RBC Capital Markets analyst Phil Nalbone kept Restore Medical, Inc. at outperform, speculative risk, and a 12-month price target of $11. The Centers for Medicare and Medicaid Services assigned the company an $850 per-procedure reimbursement rate to cover the cost of the $675 Pillar implant procedure to treat mild-to-moderate obstructive sleep apnea (OSA) in hospital outpatient settings. In addition, Restore received approval this month for sale of the Pillar Palatal Implant System in Canada, providing Canadians access to the only Food and Drug Administration-cleared palatal implant to treat snoring and mild-to-moderate OSA. Shares of the St. Paul, Minn.-based medical device company were down 8 cents, or 1.10%, at $7.19. (Nasdaq: REST)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.